Along with the increasingly serious aging of China's population, the country has also opened up the two-child policy, but although the policy has brought good conditions to many families, but also followed by a lot of trouble.
After the implementation of the universal two-child policy, the cumulative demand for fertility was released. In 2016, 17.86 million new babies were born in China, with the birth rate increasing by more than 15%. At the same time, the proportion of elderly mothers increased, and the preterm birth rate increased by nearly 10%, posing new challenges to the safety of mothers and infants.
It can be said that with the release of the second child, maternal age increase, rapid development of assisted reproductive technology, the risk of premature birth is rising. As a result, the world health organization has designated November 17 as world premature birth day, calling for people to pay attention to premature babies.
In China, the average incidence of preterm birth is 7%, the incidence of preterm birth in assisted reproduction patients is 15%-20%, and the incidence of double or multiple preterm birth is higher than 50%. Due to the congenital deficiency of premature infants, various complications will occur, and the high cost of treatment, maternal and family not only have to pay a huge economic and mental cost. More importantly, it is related to the health of premature infants. At present, domestic and foreign experts are also increasing the research on drugs for the treatment of premature birth.
The early treatment of preterm labor was from magnesium sulfate to ritodrine, to today's atosiban, and to the latest atosiban acetate injection. The development of these drugs not only makes the efficacy of drugs more excellent, but also witnesses the contribution of the development of medical treatment field to human health. It is the progress of medicine and the progress of mankind to enable those who suffer from deep pain to recover as soon as possible.
The drug, xinoan@atosiban acetate injection, is produced by chengdu shengnuo biological pharmaceutical co., ltd. to delay the onset of premature labor.
As the world's first peptide oxytocin receptor antagonist, atosiban acetate injection is the most excellent drug against preterm labor, with reliable efficacy and high safety. The drug represents an extension of the gestational period for patients with premature birth between 24 and 33 weeks, an improvement in the survival rate of preterm infants and a reduction in neonatal complications.
Premature birth is a problem of global concern with a high incidence. Contractions are one of the main symptoms of labor, it is necessary to inhibit contractions, prevent immediate premature birth, to complete the treatment of fetal lung and transfer pregnant women to the hospital with the condition of premature birth rescue to buy time.
Atosiban acetate as a national "eleventh five-year" major new drug development special varieties. It has obtained the new drug certificate H20170003 and has been listed as the first-line choice for the treatment of preterm birth by many authoritative guidelines around the world (EAPM, RCOG2011, RCOG2011, 2014 and so on).
Atosiban acetate injection is a new type of oxytocin receptor antagonist, which can effectively inhibit contractions, and is used to treat pregnant women with signs of premature labor, so as to delay the upcoming premature birth. High specificity and low incidence of adverse reactions; It can restrain contractions quickly and prolong pregnancy period effectively. Accurate, flexible, efficient and safe. It is safe, effective and accurate.
Atosiban acetate is used to delay the emergence of premature labor. According to the HDM system of CFDA southern institute of medicine, the sales of atosiban acetate increased 88% in 2016 compared with the same period last year. With the full implementation of two-child policy, the market of atosiban acetate will also grow rapidly.